Case Report
Copyright ©2013 Baishideng. All rights reserved.
World J Clin Cases. Apr 16, 2013; 1(1): 31-33
Published online Apr 16, 2013. doi: 10.12998/wjcc.v1.i1.31
Low ADAMTS-13 in plavix induced thrombotic thrombocytopenic purpura
Long Bao Cao, Christopher Jones, Assad Movahed
Long Bao Cao, Christopher Jones, Assad Movahed, Department of Cardiovascular Sciences, Brody School of Medicine, East Carolina University, Greenville, NC 27834, United States
Author contributions: Cao LB, Jones C and Movahed A contributed to the manuscript writing and revision.
Supported by The “East Carolina Heart Institute”
Correspondence to: Assad Movahed, MD, Department of Cardiovascular Sciences, Brody School of Medicine, East Carolina University, East Carolina Heart Institute, 115 Heart Drive, Mail Stop 651, Greenville, NC 27834, United States. movaheda@ecu.edu
Telephone: +1-832-3731447 Fax: +1-252-7447724
Received: October 30, 2012
Revised: December 17, 2012
Accepted: January 5, 2013
Published online: April 16, 2013
Abstract

Thrombotic thrombocytopenia purpura (TTP) was first described in 1924 as a “pathologic alteration of the microvasculature, with detachment or swelling of the endothelium, amorphous material in the sub-endothelial space, and luminal platelet aggregation leading to compromise of the microcirculation”. Ticlopidine induced TTP has been highly associated with autoimmune induced reduction in ADAMTS-13 activity. These findings, to a lesser extent, have also been found in clopidogrel induced TTP. We report a case of clopidogrel associated TTP in a patient that presented with acute stroke, renal failure, and non-ST elevation myocardial infarction.

Keywords: Plavix, Thrombotic thrombocytopenic purpura, Antiplatelet therapy